What is Altimmune's cash & equivalents?

Altimmune (ALT) reported cash & equivalents of $97.64M in Q1 2026.

How has Altimmune's cash & equivalents changed year-over-year?

Altimmune's cash & equivalents increased by 98.7% year-over-year, from $49.15M to $97.64M.

What is the long-term trend for Altimmune's cash & equivalents?

Over 5 years (2020 to 2025), Altimmune's cash & equivalents has grown at a -17.7% compound annual growth rate (CAGR), from $115.95M to $43.8M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Altimmune ALT Cash & Equivalents

Cash & Equivalents at other companies

Eli LillyLLY

$5.28B+70.8%

Merck & Co.MRK

$5.4B-38.2%

Madrigal Pharmaceuticals, Inc.MDGL

$232.19M+23.1%

Viking TherapeuticsVKTX

$118.12M+211%

Wave Life SciencesWVE

$544.59M+124%

MeiraGTx Holdings plcMGTX

$71.54M+7.5%

Other financials

Income statement

See full

Revenue$26.0K+420%

Operating income-$24.2M-11.1%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

See full

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

See full

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

See full

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

See full

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

See full

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Altimmune's cash & equivalents?: Altimmune (ALT) reported cash & equivalents of $97.64M in Q1 2026.
How has Altimmune's cash & equivalents changed year-over-year?: Altimmune's cash & equivalents increased by 98.7% year-over-year, from $49.15M to $97.64M.
What is the long-term trend for Altimmune's cash & equivalents?: Over 5 years (2020 to 2025), Altimmune's cash & equivalents has grown at a -17.7% compound annual growth rate (CAGR), from $115.95M to $43.8M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.